Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment?

Viral Immunology

Volumn 23, Issue 6, 2010, Pages 633-638

  Albayrak, Ayse ^a   Uyanik, Muhammet H ^b   Cerrah, Serkan ^b   Altas, Sare ^b   Dursun, Hakan ^b   Demir, Mehmet ^c   Uslu, Hakan ^b  

^a Erzurum Region Education and Research Hospital   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

^c MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; CHRONIC HEPATITIS; DISEASE COURSE; DRUG TARGETING; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; FEMALE; HEPATITIS B, CHRONIC; HMGB1 PROTEIN; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

HEPATITIS B VIRUS; MAMMALIA;

EID: 78650081462     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0080     Document Type: Article

References (31)

1. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-242.
2. Kiki I, Yilmaz O, Erdem F, et al.: Tumour necrosis factor-alpha levels in hepatitis B virus-related chronic active hepatitis and liver cirrhosis and its relationship to Knodell and Child-Pugh scores. Int J Clin Pract 2006;60:1075-1079.
3. Tsung A, Sahai R, Tanaka H, et al.: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201:1135-1143.
4. Wang H, Bloom O, Zhang M, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251.
5. Hamada N, Maeyama T, Kawaguchi T, et al.: The role of high mobility group box 1 in pulmonary fibrosis. Am J Re-spir Cell Mol Biol 2008;39:440-447.
6. Mullins GE, Sunden-Cullberg J, Johansson AS, et al.: Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol 2004;60:566-573.
7. Cheong JY, Cho SW, Hwang IL, et al.: Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol 2006;21:1163-1169.
8. Gutierrez-Reyes G, Gutierrez-Ruiz MC, and Kershenobich D: Liver fibrosis and chronic viral hepatitis. Arch Med Res 2007;38:644-651.
9. Rousselet MC, Michalak S, Dupre F, et al.: Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41:257-264.
10. Knodell RG, Ishak KG, Black WC, et al.: Formulation and application of a numerical scoring system for assessing his-tological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
11. Yeshua H, and Oren R: Non invasive assessment of liver fibrosis. Ann Transplant 2008;13:5-11.
12. Gutierrez-Reyes G, Lopez-Ortal P, Sixtos S, et al.: Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C. Scand J Immunol 2006;63:461-467.
13. Nair S, and Perillo RP: Hepatitis B and D. In: Hepatology. A Textbook of Liver Disease, Vol. 2, 4th ed. (Zakim D, and Boyer TD, eds.). Saunders, Philadelphia, 2003, pp. 959-1016.
14. Woloszczuk W, Troppmair W, Leiter E, et al.: Relationship of interferon-gamma and neopterin levels during stimulation with alloantigens in vivo and in vitro. Transplantation 1986;41:716-719.
15. Gulcan EM, Tirit I, Anil A, et al.: Serum neopterin levels in children with hepatitis-B-related chronic liver disease and its relationship to disease severity. World J Gastroenterol 2008;14:6840-6843.
16. Canbay A, Feldstein A, Baskin-Bey E, et al.: The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004;308: 1191-1196.
17. Pinzani M: Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched. Gut 2006;55: 310-312.
18. Hache C, and Villeneuve JP: Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother 2006;7:1835-1843.
19. Wang H, Ward MF, Fan XG, et al.: Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006;19:3-9.
20. Ilmakunnas M, Tukiainen EM, Rouhiainen A, et al.: High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl 2008;14:1517-1525.
21. Scaffidi P, Misteli T, and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-195.
22. Ito I, Fukazawa J, and Yoshida M: Post-translational meth-ylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 2007;282:16336-16344.
23. Andersson U, Wang H, Palmblad K, et al.: High mobility group 1 protein (HMG-1) stimulates proinflammatory cy-tokine synthesis in human monocytes. J Exp Med 2000; 192:565-570.
24. Raucci A, Palumbo R, and Bianchi ME: HMGB1: A signal of necrosis. Autoimmunity 2007;40:285-289.
25. Mitola S, Belleri M, Urbinati C, et al.: Cutting edge: Extracellular high mobility group box-1 protein is a proangio-genic cytokine. J Immunol 2006;176:12-15.
26. Sitia G, Iannacone M, Mü ller S, et al.: Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007;81:100-107.
27. Guidotti LG, and Chisari FV: Immunobiology and pathogen-esis of viral hepatitis. Annu Rev Pathol Mech Dis 2006;1:23-61.
28. Klune JR, Dhupar R, Cardinal J, et al.: HMGB1: endogenous danger signaling. Mol Med 2008;14:476-484.
29. Tsung A, Klune JR, Zhang X, et al.: HMGB1 release induced by liver ischemia involves toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007;204:2913-2923.
30. Jiang W, Bell CW, and Pisetsky DS: The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccha-ride or polyinosinic-polycytidylic acid. J Immunol 2007;178: 6495-6503.
31. Jiang W, and Pisetsky DS: The role of IFNalpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysac-charide. J Immunol 2006;177:3337-3343.